Recursion's REC-4881 shows 47% median reduction in polyp burden in Phase 2 FAP trial

• Recursion reported positive Phase 2 TUPELO trial results for oral REC-4881 in familial adenomatous polyposis.
• The results were presented at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer annual meeting.
• Treatment reduced polyp burden across the upper and lower gastrointestinal tract, including larger, higher-risk polyps; reductions persisted off treatment in most patients.
• No new safety signals emerged, with most treatment-related adverse events mild or moderate.
• A registrational trial is expected to begin in the second half of 2027, pending ongoing FDA discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611021625PRIMZONEFULLFEED9868436) on November 02, 2026, and is solely responsible for the information contained therein.